Optimal primary surgical treatment for advanced epithelial ovarian cancer (Q24234923)

title

Optimal primary surgical treatment for advanced epithelial ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457688&resulttype=core&format=json

13 May 2020

1 reference

Ahmed Elattar

1

Ahmed

Elattar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457688&resulttype=core&format=json

13 May 2020

Andrew Bryant

2

Andrew

Bryant

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457688&resulttype=core&format=json

13 May 2020

Brett A Winter-Roach

3

Brett A

Winter-Roach

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457688&resulttype=core&format=json

13 May 2020

Mohamed Hatem

4

Mohamed

Hatem

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457688&resulttype=core&format=json

13 May 2020

Raj Naik

5

Raj

Naik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457688&resulttype=core&format=json

Cochrane Database of Systematic Reviews

13 May 2020

publication date

10 August 2011

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457688&resulttype=core&format=json

13 May 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457688&resulttype=core&format=json

13 May 2020

page(s)

CD007565

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457688&resulttype=core&format=json

Identification of prognostic factors in advanced epithelial ovarian carcinoma

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Stage III and IV ovarian cancer in the South West of England: five-year outcome analysis for cases treated in 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Natural history of stage IV epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

The role of bowel surgery with cytoreduction for epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

"MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Treatment of advanced ovarian carcinoma in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Carboplatin with cyclophosphamide in patients with advanced ovarian cancer: an efficacy and quality-adjusted survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residu

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Selection of patients and staging of peritoneal surface malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

A critique of surgical cytoreduction in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Role of surgery in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Role of primary surgery in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Age-specific ovarian cancer incidence rate patterns in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Treatment of patients with early epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Influence of surgery and postoperative therapy and tumor characteristics on patient prognosis in advanced ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Ifosfamide plus Cisplatin as Primary Chemotherapy of Advanced Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

Cytoreductive surgery for stage IV epithelial ovarian cancer

21 January 2018

1 reference

12 December 2020

FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology

1 reference

12 December 2020

Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study

1 reference

12 December 2020

Novel, dose intensive, single-agent cisplatin in the first-line management of advanced stage ovarian cancer

1 reference

12 December 2020

Therapeutic strategy in the management of stage II-IV epithelial ovarian carcinoma

1 reference

12 December 2020

[Interest in intestinal resection for treatment of advanced ovarian cancer]

1 reference

12 December 2020

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

12 December 2020

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.

1 reference

12 December 2020

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma

1 reference

12 December 2020

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial

1 reference

12 December 2020

[A study of prognostic factors of stage IV epithelial ovarian cancer]

1 reference

12 December 2020

Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?

1 reference

12 December 2020

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

1 reference

12 December 2020

The effect of centralization of primary surgery on survival in ovarian cancer patients

1 reference

12 December 2020

The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: "maintenance" therapy reconsidered

1 reference

12 December 2020

HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.

1 reference

12 December 2020

Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study

1 reference

12 December 2020

Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?

1 reference

12 December 2020

Secondary surgical cytoreduction for advanced ovarian carcinoma

1 reference

12 December 2020

Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer

1 reference

12 December 2020

Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer

1 reference

12 December 2020

Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial

1 reference

12 December 2020

Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?

1 reference

12 December 2020

Aggressive surgical effort and improved survival in advanced-stage ovarian cancer

1 reference

12 December 2020

Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer

1 reference

12 December 2020

Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer

1 reference

12 December 2020

1 reference

12 December 2020

Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary

1 reference

12 December 2020

Morbidity and mortality associated with primary and repeat operations for ovarian cancer.

1 reference

12 December 2020

Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (A

1 reference

12 December 2020

Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics

1 reference

12 December 2020

Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis

1 reference

12 December 2020

Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action

1 reference

12 December 2020

Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study

1 reference

12 December 2020

Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer

1 reference

12 December 2020

The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer

1 reference

12 December 2020

Cancer statistics, 2008

1 reference

12 December 2020

Five-year survival for cisplatin-based chemotherapy versus single-agent melphalan in patients with advanced ovarian cancer and optimal debulking surgery

1 reference

12 December 2020

Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (hac) vs. cisplatin, adriamycin, cyclophosphamide (pac) in advanced ovarian cancer: long-term results

1 reference

12 December 2020

Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma

1 reference

12 December 2020

Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study.

1 reference

12 December 2020

Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center

1 reference

12 December 2020

New terminology for cytoreduction in advanced ovarian cancer

1 reference

12 December 2020

Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study

1 reference

12 December 2020

A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study

1 reference

12 December 2020

A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group

1 reference

12 December 2020

Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide

1 reference

12 December 2020

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Prognostic factors in advanced ovarian carcinoma

1 reference

12 December 2020

Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer

1 reference

12 December 2020

Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma

1 reference

12 December 2020

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

12 December 2020

Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study.

1 reference

12 December 2020

The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma

1 reference

12 December 2020

Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.

1 reference

12 December 2020

Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases

1 reference

12 December 2020

Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study

1 reference

12 December 2020

Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?

1 reference

12 December 2020

Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer

1 reference

12 December 2020

The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007565.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD007565.PUB2

2 references

Consolidated OpenCitations Corpus – April 2017

3567311

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457688&resulttype=core&format=json

release_yzu4kacj3baurgudrq3m6hz5eq

13 May 2020

Fatcat ID

0 references

3567311

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457688&resulttype=core&format=json

13 May 2020

PubMed publication ID

21833960

2 references

Consolidated OpenCitations Corpus – April 2017

3567311